Evidence map›Paper›PMID 36325064›Full record

ReviewiScience2022

Immunotherapy approaches for hematological cancers.

Olivia L Lanier, Edgar Pérez-Herrero, Abielle P D ' Andrea, Kiana Bahrami, Elaine Lee, Deidra M Ward, Nilaya Ayala-Suárez, Sheyla M Rodríguez-Méndez, Nicholas A Peppas

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Drug delivery methods for cancer immunotherapy.Drug delivery and translational research · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Olivia L LanierDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Edgar Pérez-HerreroDepartamento de Ingeniería Química y Tecnología Farmacéutica, Universidad de La Laguna, La Laguna, 38206 Tenerife, Spain.
Abielle P D ' AndreaDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Kiana BahramiDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Elaine LeeDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.
Deidra M WardDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Nilaya Ayala-SuárezInstituto Universitario de Bio-Orgánica Antonio González, Universidad de La Laguna, La Laguna, 38206 Tenerife, Spain.
Sheyla M Rodríguez-MéndezInstituto Universitario de Bio-Orgánica Antonio González, Universidad de La Laguna, La Laguna, 38206 Tenerife, Spain.
Nicholas A PeppasDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematological cancers such as leukemia, lymphoma, and multiple myeloma have traditionally been treated with chemo and radiotherapy approaches. Introduction of immunotherapies for treatment of these diseases has led to patient remissions that would not have been possible with traditional approaches. In this critical review we identify main disease characteristics, symptoms, and current treatment options. Five common immunotherapies, namely checkpoint inhibitors, vaccines, cell-based therapies, antibodies, and oncolytic viruses, are described, and their applications in hematological cancers are critically discussed.

Indexed as

Biological sciencesCancerHealth sciencesImmunologyOncology

Identifiers

PMID36325064
PMCPMC9619355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.